Among the considerable anticancer agents, curcumin (CU) drug has been confirmed to be very extraordinary towards any type of cancer cells. Chitosan coated core–shell nanocarrier was prepared and used as a nano-carrier for encapsulation of CU drug (Fe@Au-CU-CS-FA NP’s) through a reverse micro-emulsion method. Each shape and size and polydispersity (PDI) properties in addition to the contents of Fe@Au core–shell and Fe@Au-CU-CS-FA NP’s were studied utilizing zeta potential particles analyzer, Atomic Force Microscope, Scanning Electron Microscopy, Energy Dispersive X-rays spectroscopy, and High-Resolution Transmission Electron Microscopy. On the other hand, those nanosystems characterized by UV–Visible spectrophotometer. Fe@Au NP’s possess a nearly uniform size of around ~ 63.65 nm and a spherical form as core–shell at temperature 38 °C and the Fe@Au-CU-CS-FA NP’s possess a nearly uniform size of around 206.5 nm and a spherical form. EDX results for Fe@Au core–shell structure show percentage ratio of (Fe, Au) elements, and the results of Fe@Au-CU-CS-FA NP’s show percentage ratio of (Fe, Au, C, O, N) elements. Fe@Au-CU-CS-FA NP’s use as drug delivery to treat different types of cancers. Finally, the results showed that synthesized nanosystems are noticeably potent for cancer therapy purposes due to their suitable characteristics such as small size, spherical shape, negligible aggregation, good polydispersity (PDI), correct content and appropriate magnetic responsive properties. This Fe@Au-CU-CS-FA also exhibited a controlled release of CU at 37 °C in (7.4) and (5.4) pH. Afterward, the ideal dose and therapeutic effects of (Fe@Au-CU-CS-FA) for lung cancer and normal cell lines were evaluated through MTT assay. Then the flow cytometry assay shows significant cell apoptosis induction by Fe@Au-CU-CS-FA. The results confirmed that Fe@Au-CU-CS-FA retained considerable antitumor effects; no adverse consequences were detected for normal cells.